Kapil Soni, V. Arora, Amita Chaudhary, H. Kumar, R. Tanwar, N. Sharma, S. Jakhar, Bhuvanesh Purohit
Aim: The purpose of this study is to compare local tumor control, dysphagia-free survival, and complication in patients with locally advanced carcinoma esophagus using external beam radiotherapy (EBRT) alone (Arm A) and EBRT followed by intraluminal brachytherapy (ILBT) (Arm B). Materials and Methods: A total of 50 histopathologically proven patients of locally advanced unresectable cancer esophagus were taken for the study from March 2019 to February 2020 and were divided into two arms, 25 patients each. Arm A was treated by standard concurrent chemotherapy–radiotherapy (CTRT) alone (a total dose of 50 Gray (Gy) in 25 fractions (fr), 2 Gy/fr administered daily 5 days per week with weekly injection cisplatin 40 mg/m2) and Arm B received 44 Gy through two definitive radiation therapies along with computed tomography followed by ILBT (5 Gy/fr; 2 fr 1 week apart). Assessment was done weekly during RT and 3 and 6 months post treatment for local control of disease and dysphagia-free survival and complication. Results: The local tumor control was observed 80% and 84% at 6 months in Arm A and Arm B, respectively (P = 0.82). Six-month dysphagia-free survival was 52% versus 68% (P = 0.248) and stricture formation was found 16% and 24% (P = 0.479) in Arm A and Arm B, respectively. Conclusion: This study shows comparable results of CTRT-ILBT over CTRT alone in locally advanced esophageal cancer patients.
{"title":"Comparative Study between conventional EBRT alone and EBRT followed by intraluminal brachytherapy in local advanced cancer esophagus","authors":"Kapil Soni, V. Arora, Amita Chaudhary, H. Kumar, R. Tanwar, N. Sharma, S. Jakhar, Bhuvanesh Purohit","doi":"10.4103/jrcr.jrcr_45_21","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_45_21","url":null,"abstract":"Aim: The purpose of this study is to compare local tumor control, dysphagia-free survival, and complication in patients with locally advanced carcinoma esophagus using external beam radiotherapy (EBRT) alone (Arm A) and EBRT followed by intraluminal brachytherapy (ILBT) (Arm B). Materials and Methods: A total of 50 histopathologically proven patients of locally advanced unresectable cancer esophagus were taken for the study from March 2019 to February 2020 and were divided into two arms, 25 patients each. Arm A was treated by standard concurrent chemotherapy–radiotherapy (CTRT) alone (a total dose of 50 Gray (Gy) in 25 fractions (fr), 2 Gy/fr administered daily 5 days per week with weekly injection cisplatin 40 mg/m2) and Arm B received 44 Gy through two definitive radiation therapies along with computed tomography followed by ILBT (5 Gy/fr; 2 fr 1 week apart). Assessment was done weekly during RT and 3 and 6 months post treatment for local control of disease and dysphagia-free survival and complication. Results: The local tumor control was observed 80% and 84% at 6 months in Arm A and Arm B, respectively (P = 0.82). Six-month dysphagia-free survival was 52% versus 68% (P = 0.248) and stricture formation was found 16% and 24% (P = 0.479) in Arm A and Arm B, respectively. Conclusion: This study shows comparable results of CTRT-ILBT over CTRT alone in locally advanced esophageal cancer patients.","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86437004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metformin use and Occurrence of Hepatocellular Carcinoma in Patients with Type II Diabetes Mellitus: A Systematic Review","authors":"Ketan Garg, AchalGaniga Lingaraj, Shisheer Havangi, A. Satheesha, Arjun Naidu, Bhawna Garg","doi":"10.4103/jrcr.jrcr_65_22","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_65_22","url":null,"abstract":"","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74825330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Unresectable head-and-neck cancers (HNCs) pose a significant challenge to clinical oncologists. Radiotherapy (RT) has a pivotal role in palliation of symptoms in advanced unresectable stage. Palliative RT protocols generally employ hypofractionated regimes in an attempt to reduce the overall treatment time and acute toxicities. Concurrent chemoradiotherapy (CCRT) may improve local control facilitating faster palliation of symptoms. Yet the role of chemotherapy with hypofractionated schedules is unclear in palliative settings due to the fear of increased toxicities. The literature review was hence conducted to validate the tolerability and efficacy of CCRT in the palliative setting. The literature search was performed on electronic databases using appropriate keywords. Studies evaluating untreated patients, treated recurrent cancers, second primaries localized in the head and neck or metastatic HNC were all chosen. Five studies were selected which met our selection criteria. Palliation of symptoms, response rates, and toxicities of these studies was evaluated. Role of such concurrent regimes at other sites have also been discussed. All the evaluated studies demonstrated good rates of symptom palliation and response rates with tolerable adverse effects. In addition, our literature review has identified a paucity of evidence that warrants large-scale longitudinal studies to derive conclusive remarks on the use of palliative CCRT.
{"title":"Role of addition of chemotherapy to palliative radiotherapy protocol: A review of literature and experience from a tertiary cancer center of India","authors":"P. Venkata Ramana, Gulafshan Jabi, Mohsin Khan","doi":"10.4103/jrcr.jrcr_31_22","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_31_22","url":null,"abstract":"Unresectable head-and-neck cancers (HNCs) pose a significant challenge to clinical oncologists. Radiotherapy (RT) has a pivotal role in palliation of symptoms in advanced unresectable stage. Palliative RT protocols generally employ hypofractionated regimes in an attempt to reduce the overall treatment time and acute toxicities. Concurrent chemoradiotherapy (CCRT) may improve local control facilitating faster palliation of symptoms. Yet the role of chemotherapy with hypofractionated schedules is unclear in palliative settings due to the fear of increased toxicities. The literature review was hence conducted to validate the tolerability and efficacy of CCRT in the palliative setting. The literature search was performed on electronic databases using appropriate keywords. Studies evaluating untreated patients, treated recurrent cancers, second primaries localized in the head and neck or metastatic HNC were all chosen. Five studies were selected which met our selection criteria. Palliation of symptoms, response rates, and toxicities of these studies was evaluated. Role of such concurrent regimes at other sites have also been discussed. All the evaluated studies demonstrated good rates of symptom palliation and response rates with tolerable adverse effects. In addition, our literature review has identified a paucity of evidence that warrants large-scale longitudinal studies to derive conclusive remarks on the use of palliative CCRT.","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86304869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shahida Nasreen, Mansoora Akhter, Asifa Andleeb, ArshadManzoor Najumi, ShowketAhmad Dar, S. Banday, Shaqul Qamar, K. Fatima, Shaiba Hussain, R. Akhter, M. Sofi, T. Tali, N. Dar, Ulfat Ara
{"title":"Metastasis in carcinoma esophagus: Clinical profile and survival","authors":"Shahida Nasreen, Mansoora Akhter, Asifa Andleeb, ArshadManzoor Najumi, ShowketAhmad Dar, S. Banday, Shaqul Qamar, K. Fatima, Shaiba Hussain, R. Akhter, M. Sofi, T. Tali, N. Dar, Ulfat Ara","doi":"10.4103/jrcr.jrcr_19_23","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_19_23","url":null,"abstract":"","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82811883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Non-ionizing radiations and their biochemical and biomedical impacts: A review","authors":"Yogendrakumar H. Lahir","doi":"10.4103/jrcr.jrcr_17_22","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_17_22","url":null,"abstract":"","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74337666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Radiation tolerance in geriatric patients: A retrospective observational study","authors":"Neerudu Pragnahitha, Arpitha S Rao","doi":"10.4103/jrcr.jrcr_92_22","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_92_22","url":null,"abstract":"","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78885340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Context: Radioimmunotherapy is an emerging treatment modality for various types of cancers. While immunotherapy using monoclonal antibodies has shown promising results, particularly in hematological malignancies, a significant number of patients develop resistance to the treatment, which may be overcome using monoclonal antibodies labeled with suitable therapeutic radioisotopes. Aim: In this study, in vitro evaluation studies of 177Lu-CHX-A''-DTPA-rituximab were performed in Raji cells that overexpress CD20. The extent of internalization of 177Lu-CHX-A”-DTPA rituximab inside the target cell as well as the impact of cellular toxicity in Raji cells was studied. Materials and Methods: The monoclonal antibody rituximab was labeled with 177Lu using CHX-A”-DTPA as the bifunctional chelator. In vitro cell binding and inhibition studies were performed in Raji cells to ascertain the specificity of the radioimmunoconjugate toward the CD20 receptors. The immunoreactive fraction was determined to evaluate the integrity of the radioimmunoconjugate. A cellular internalization assay was performed to evaluate the extent of internalization of the radioimmunoconjugate, and the extent of cytotoxicity was determined using flow cytometry in comparison with unlabeled rituximab. Results: Radiochemical purity of 177Lu-CHX-A''-DTPA-rituximab was determined to be 97.4% ± 1%. In vitro cell-binding studies in Raji cells showed a cell concentration-dependent increase in the percent cell binding, which surged from 11.7% ± 0.7% to 22.7% ± 0.9%, as the cell concentration increased from 0.94 × 10^6 to 7.5 × 10^6 successively. Inhibition in binding was observed in the presence of unlabeled rituximab (11.7% ± 0.7% to 7.8% ± 1.2% and from 22.7% ± 0.9% to 12.1% ± 1.3%). The immunoreactive fraction was found to be 78.5%. A time-dependent increase in the cellular internalization from 25.21 ± 1.7 to 60.47 ± 0.20 was observed. The percent cell viability decreased from 56% to 41% when the cell was treated with rituximab compared with 177Lu-rituximab. Conclusions: Thus, the results show a potential of 177Lu-rituximab as a promising radiopharmaceutical against non-Hodgkin's lymphoma.
{"title":"Fate of 177Lu-CHX-A”-DTPA-Rituximab: In vitro Evaluation in Raji Cell Line","authors":"Saloni Samant, C. Kumar, U. Pandey","doi":"10.4103/jrcr.jrcr_15_22","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_15_22","url":null,"abstract":"Context: Radioimmunotherapy is an emerging treatment modality for various types of cancers. While immunotherapy using monoclonal antibodies has shown promising results, particularly in hematological malignancies, a significant number of patients develop resistance to the treatment, which may be overcome using monoclonal antibodies labeled with suitable therapeutic radioisotopes. Aim: In this study, in vitro evaluation studies of 177Lu-CHX-A''-DTPA-rituximab were performed in Raji cells that overexpress CD20. The extent of internalization of 177Lu-CHX-A”-DTPA rituximab inside the target cell as well as the impact of cellular toxicity in Raji cells was studied. Materials and Methods: The monoclonal antibody rituximab was labeled with 177Lu using CHX-A”-DTPA as the bifunctional chelator. In vitro cell binding and inhibition studies were performed in Raji cells to ascertain the specificity of the radioimmunoconjugate toward the CD20 receptors. The immunoreactive fraction was determined to evaluate the integrity of the radioimmunoconjugate. A cellular internalization assay was performed to evaluate the extent of internalization of the radioimmunoconjugate, and the extent of cytotoxicity was determined using flow cytometry in comparison with unlabeled rituximab. Results: Radiochemical purity of 177Lu-CHX-A''-DTPA-rituximab was determined to be 97.4% ± 1%. In vitro cell-binding studies in Raji cells showed a cell concentration-dependent increase in the percent cell binding, which surged from 11.7% ± 0.7% to 22.7% ± 0.9%, as the cell concentration increased from 0.94 × 10^6 to 7.5 × 10^6 successively. Inhibition in binding was observed in the presence of unlabeled rituximab (11.7% ± 0.7% to 7.8% ± 1.2% and from 22.7% ± 0.9% to 12.1% ± 1.3%). The immunoreactive fraction was found to be 78.5%. A time-dependent increase in the cellular internalization from 25.21 ± 1.7 to 60.47 ± 0.20 was observed. The percent cell viability decreased from 56% to 41% when the cell was treated with rituximab compared with 177Lu-rituximab. Conclusions: Thus, the results show a potential of 177Lu-rituximab as a promising radiopharmaceutical against non-Hodgkin's lymphoma.","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80227847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Rather, Aijaz A. Khan, F. Mir, M. A. Badhul Haq
Purpose: The purpose of the current study is to determine whether patients diagnosed with glioblastoma multiforme (GBM) who underwent radiotherapy (RT) using intensity-modulated RT (IMRT) technique were benefitting from this highly conformal treatment in terms of doses received by planning target volume (PTV) and organs at risk (OARs) in comparison to three-dimensional conventional RT (3DCRT). Materials and Methods: Twelve patients treated with IMRT for GBM were selected for dosimetric comparison with 3DCRT. The prescribed dose was 60 Gy in 30 fractions and seven non-coplanner beams were used in IMRT to cover 95% of target volume. The irradiated patients of GBM were retrieved and replanned with 3DCRT techniques. Dosimetric comparison was done by performing two plans for the same patient; prescription dose and normal tissue constraints were identical for both plans. The dose–volume histograms of target volumes and OAR, dose conformity, and dose homogeneity with 3DCRT and IMRT planning were compared. Statistical analysis was performed to determine the differences. Results: The mean conformity index was 0.99 ± 0.001 for IMRT and 0.97 ± 0.002 for 3DCRT, P = 0.001. The mean homogeneity index was 1.03 ± 0.02 for IMRT and 1.06 ± 0.009 for 3DCRT, P = 0.003, which is statistically significant. The IMRT technique enables dose reduction of normal tissues including brainstem (Dmean by 33.78 ± 5.34 and Dmax 51.84 ± 4.43), optic chiasm (Dmean by 36.92 ± 1.99 and Dmax 44.61 ± 3.72), left optic nerve (Dmean by 28.97 ± 6.51 and Dmax 46.08 ± 10.58), right optic nerve (Dmean by 31.93 ± 11.68 and Dmax 44.63 ± 13.54), left eye (Dmean by 18.66 ± 8.92 and Dmax 37.43 ± 13.47), right eye (Dmean by 14.40 ± 4.87 and Dmax 40.37 ± 11.37), left lens (by Dmax 5.45 ± 1.85), and right lens (Dmax 5.07 ± 0.63). Conclusion: The IMRT provides a real dosimetric advantage, especially for normal brain tissue, and in terms of target coverage. It allows treatment of tumors while respecting OARs' dose constraints. The IMRT technique shows significant advantage in PTV coverage, dose homogeneity, and conformity. In IMRT, the coverage is better where PTV was overlapping with critical OARs.
{"title":"Dosimetric comparative study of conformal radiation techniques in patients with glioblastoma multiforme","authors":"S. Rather, Aijaz A. Khan, F. Mir, M. A. Badhul Haq","doi":"10.4103/jrcr.jrcr_19_22","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_19_22","url":null,"abstract":"Purpose: The purpose of the current study is to determine whether patients diagnosed with glioblastoma multiforme (GBM) who underwent radiotherapy (RT) using intensity-modulated RT (IMRT) technique were benefitting from this highly conformal treatment in terms of doses received by planning target volume (PTV) and organs at risk (OARs) in comparison to three-dimensional conventional RT (3DCRT). Materials and Methods: Twelve patients treated with IMRT for GBM were selected for dosimetric comparison with 3DCRT. The prescribed dose was 60 Gy in 30 fractions and seven non-coplanner beams were used in IMRT to cover 95% of target volume. The irradiated patients of GBM were retrieved and replanned with 3DCRT techniques. Dosimetric comparison was done by performing two plans for the same patient; prescription dose and normal tissue constraints were identical for both plans. The dose–volume histograms of target volumes and OAR, dose conformity, and dose homogeneity with 3DCRT and IMRT planning were compared. Statistical analysis was performed to determine the differences. Results: The mean conformity index was 0.99 ± 0.001 for IMRT and 0.97 ± 0.002 for 3DCRT, P = 0.001. The mean homogeneity index was 1.03 ± 0.02 for IMRT and 1.06 ± 0.009 for 3DCRT, P = 0.003, which is statistically significant. The IMRT technique enables dose reduction of normal tissues including brainstem (Dmean by 33.78 ± 5.34 and Dmax 51.84 ± 4.43), optic chiasm (Dmean by 36.92 ± 1.99 and Dmax 44.61 ± 3.72), left optic nerve (Dmean by 28.97 ± 6.51 and Dmax 46.08 ± 10.58), right optic nerve (Dmean by 31.93 ± 11.68 and Dmax 44.63 ± 13.54), left eye (Dmean by 18.66 ± 8.92 and Dmax 37.43 ± 13.47), right eye (Dmean by 14.40 ± 4.87 and Dmax 40.37 ± 11.37), left lens (by Dmax 5.45 ± 1.85), and right lens (Dmax 5.07 ± 0.63). Conclusion: The IMRT provides a real dosimetric advantage, especially for normal brain tissue, and in terms of target coverage. It allows treatment of tumors while respecting OARs' dose constraints. The IMRT technique shows significant advantage in PTV coverage, dose homogeneity, and conformity. In IMRT, the coverage is better where PTV was overlapping with critical OARs.","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81397037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Major recommendations from the 5th Asian congress of radiation research for basic and applied radiobiology research","authors":"Ajay Kumar, B. Pandey, K. Mishra","doi":"10.4103/jrcr.jrcr_26_23","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_26_23","url":null,"abstract":"","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90527274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aashita, Rajiv Sharma, Vikas K Yadav, T. Divya, N. Kaur
Primary soft-tissue sarcomas of the paratesticular region are uncommon tumors comprising 1% of all adult sarcomas. Paratesticular epithelioid sarcoma (ES) is a rare subtype. Here, we report the case of a 68-years-old male with scrotal swelling who underwent high inguinal exploration and right orchidectomy. Histopathology and immunohistochemistry revealed paratesticular ES. Very few cases of paratesticular ES have been reported so far in the literature. Clinical presentation, investigations, treatment interventions, and prognosis have been discussed. As it can be confused with other benign and malignant conditions, diagnosis is often made on histopathological evaluation.
{"title":"Paratesticular epithelioid sarcoma: A rare case","authors":"Aashita, Rajiv Sharma, Vikas K Yadav, T. Divya, N. Kaur","doi":"10.4103/jrcr.jrcr_8_22","DOIUrl":"https://doi.org/10.4103/jrcr.jrcr_8_22","url":null,"abstract":"Primary soft-tissue sarcomas of the paratesticular region are uncommon tumors comprising 1% of all adult sarcomas. Paratesticular epithelioid sarcoma (ES) is a rare subtype. Here, we report the case of a 68-years-old male with scrotal swelling who underwent high inguinal exploration and right orchidectomy. Histopathology and immunohistochemistry revealed paratesticular ES. Very few cases of paratesticular ES have been reported so far in the literature. Clinical presentation, investigations, treatment interventions, and prognosis have been discussed. As it can be confused with other benign and malignant conditions, diagnosis is often made on histopathological evaluation.","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87800855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：